Top Markets
Coin of the day
Sorrento Therapeutics, Inc. Sorrento Therapeutics, Inc.

Sorrento Therapeutics, Inc.

0L85
शेयरों में रैंक #37352
Sorrento Therapeutics, Inc. is a biopharmaceutical firm, active in both... Sorrento Therapeutics, Inc. is a biopharmaceutical firm, active in both clinical development and commercialization, dedicated to creating treatments across a broad spectrum of illnesses, including cancer, autoimmune conditions, inflammatory disorders, viral infections, and neurodegenerative diseases. The company conducts its operations through two distinct divisions: Sorrento Therapeutics and Scilex. For cancer treatment, Sorrento employs its unique G-MAB antibody library alongside sophisticated targeted delivery methods. These include chimeric and dimeric antigen receptor T-cell (CAR-T) therapies, antibody-drug conjugates, and bispecific antibody strategies. Additionally, its Sofusa drug delivery system enables the direct administration of biologics into the lymphatic system. Sorrento's pipeline features several clinical-stage programs. These encompass an anti-CD38 CAR-T therapy targeting multiple myeloma, amyloidosis, and graft-versus-host disease. The company is also advancing resiniferatoxin, a non-opioid TRPV1 agonist neurotoxin, for managing pain associated with late-stage cancer and osteoarthritis of the knee. Furthermore, ZTlido, a lidocaine delivery system, addresses postherpetic neuralgia. In the realm of pain management, SEMDEXA, an injectable viscous gel, is undergoing Phase III trials for sciatica (a form of lower back pain); SP-103, an experimental non-aqueous lidocaine topical system, is being developed for chronic low back pain; and SP-104 is a novel, low-dose, delayed-release naltrexone hydrochloride formulation for fibromyalgia. The company maintains several strategic collaborations, including a partnership with SmartPharm Therapeutics Inc. for a gene-encoded antibody vaccine against COVID-19, and with Celularity, Inc. for a Phase I/II clinical trial involving up to 94 COVID-19 patients. Additionally, Sorrento works with Mount Sinai Health System on COVI-SHIELD, an antibody treatment for SARS-CoV-2 infection, and with Mayo Clinic on a Phase Ib pilot study utilizing Sofusa technology for Ipilimumab delivery in melanoma patients. Established in 2006, Sorrento Therapeutics operates from its headquarters in San Diego, California.
शेयर मूल्य
$0.0033
अंतिम समन्वयन: 2026-02-26
मार्केट कैप
$1.79M
बदलाव (1 दिन)
-21.43%
बदलाव (1 वर्ष)
371.43%
देश
US
व्यापार Sorrento Therapeutics, Inc. (0L85)

श्रेणी

Sorrento Therapeutics, Inc. (0L85) के लिए स्टॉक मूल्य इतिहास
दिन का सबसे उच्च समापन मूल्य: $0.00 (2026-02-01 को)

दिन का सबसे निम्न समापन मूल्य: $7.66 (2018-01-01 को)
Sorrento Therapeutics, Inc. के स्टॉक मूल्य का इतिहास 2018 से 2026 तक
प्रत्येक वर्ष के अंत में स्टॉक मूल्य प्रदर्शन
वर्ष प्रदर्शन
2026 (TTM) -55.40%
2025 408.33%
2024 -97.87%
2023 -94.47%
2022 -81.87%
2021 -25.41%
2020 116.28%
2019 1.65%
2018 0.00%
समान कंपनियों या प्रतिस्पर्धियों के स्टॉक मूल्य
कंपनी स्टॉक मूल्य परिवर्तन 1व% देश
$58.56 61.10%
US
$49.19 71.73%
SE
$185.04 40.51%
FR
$62.27 4.40%
IT
$114.37 59.39%
US